enGene appoints Ron Cooper as CEO, promotes Raj Pruthi to CMO; Hanson departs as planned

enGene Therapeutics Inc.

Ron Cooper appointed CEO and director effective July 22, 2024; Jason Hanson resigns but remains as strategic advisor.
Cooper receives $700k base salary, 60% bonus target, and inducement option for 1.25M shares at $8.81, vesting over 4 years.
Raj Pruthi promoted to CMO succeeding Richard Bryce, who departed July 19, 2024.
Hanson's transition amendment provides $390k severance payment; retains consulting role at $25k/month for 6 months.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Jason D. Hanson

Chief Executive Officer

ENGN · enGene Therapeutics Inc.

Effective: 2024-07-21
Successor: Ronald H.W. Cooper
Filed: July 24, 2024, 7:59 PM ET

Mr. Hanson’s separation from the Company and resignation as a director became effective July 21, 2024, and his resignation is not the result of any disagreement with the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jason D. Hanson resigned as Chief Executive Officer at enGene Therapeutics Inc..

Action: resigned
Role: Chief Executive Officer

Exact text from the filing

Mr. Hanson’s separation from the Company and resignation as a director became effective July 21, 2024, and his resignation is not the result of any disagreement with the Company.

View on SEC.gov

enGene Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-183292

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.